FDA grants emergency use authorization for Zoetis drug to treat screwworm in dogs

Key facts

• The FDA issued an emergency use authorization for Zoetis' Simparica TRIO to treat New World screwworm infestations in dogs.
• The authorization is for situations where no alternative treatments are available during public health threats.
• Screwworm infestations have been identified in specific areas of Texas and New Mexico.
• Dogs in or traveling to affected areas should be monitored for signs of infestation.
• Simparica TRIO was originally approved in 2020 for heartworm, flea, and tick indications.

The U.S. Food and Drug Administration (FDA) has granted an emergency use authorization for Zoetis' Simparica TRIO, a prescription medication primarily used for heartworm, flea, and tick prevention in dogs. This authorization allows for its use in treating New World screwworm (NWS) infestations in dogs and puppies.